Avrupa Birliği - Estonca - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriaas - immunosupressandid - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkootikumid luuhaiguste raviks - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

paion deutschland gmbh - eravacycline - infection; bacterial infections - antibacterials süsteemseks kasutamiseks, - xerava on näidustatud ravi keeruline intra-kõhuõõne infektsioonid (ciai) täiskasvanutel. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

santen oy - tsüklosporiin - conjunctivitis; keratitis - oftalmoloogilised vahendid - ravi raskeid kevadine keratoconjunctivitis (vkc) lastele alates 4 aasta vanusest ja noorukid.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

intervet international b.v. - live myxoma vectored rhd viiruse tüve, 009, live myxoma vectored rhd viiruse tüve mk1899 - immunoloogilised ravimid jaoks jäneslased - küülikud - aktiivse immuniseerimise küülikud alates 5. elunädalast aastast vähendada suremust ja kliinilisi tunnuseid müksomatoosi ja küülikute hemorraagiline haigus (rhd), mis on põhjustatud klassikalise rhd viirus (rhdv1) ja rhd virus tüüp 2 (rhdv2).

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - ciclesonide - hingamiselundite muud ravimid hingamisteede obstruktiivsete haiguste, inhalants - hobused - eest leevendamine kliinilised tunnused on raske hobuste astma (varem tuntud korduvad hingamisteede obstruktsioon – (rao), suvel karjamaal seotud korduvate hingamisteede obstruktsioon – (spa-rao)).

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - osteoporoos - narkootikumid luuhaiguste raviks - evenity on näidustatud ravi raske osteoporoosi puhul postmenopausis naistel on suur risk luumurdude.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - muud närvisüsteemi ravimid - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mitu müeloomit - antineoplastilised ained - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.